Form 4: Protagonist CFO Sells Shares After Option Exercise

Protagonist Therapeutics CFO Asif Ali exercised stock options and subsequently sold a portion of his common stock holdings for a significant profit.

Summary

• Asif Ali, Chief Financial Officer of Protagonist Therapeutics, Inc. (PTGX), engaged in a series of transactions on March 26, 2026.
• He exercised stock options to acquire 19,500 shares of common stock at an exercise price of $19.19 per share.
• He also exercised stock options to acquire 5,265 shares of common stock at an exercise price of $12.17 per share.
• Concurrently, he sold 24,765 shares of common stock at a weighted average price of $104.24 per share, with individual sales ranging from $104.00 to $104.465.
• Following these transactions, his direct beneficial ownership of common stock decreased from 85,518 shares (which included 433 shares acquired via ESPP on March 9, 2026) to 60,753 shares.
• He retains unexercised stock options for 31,300 shares (from an April 18, 2022 grant) and 13,282 shares (from a January 16, 2023 grant).

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral-to-slightly-negative signal. While the exercise of options indicates value realization, the subsequent net sale of shares by a key executive like the CFO can sometimes be interpreted cautiously by the market, despite being a common practice for personal financial management.

Positives

• The CFO exercised options, indicating value in the underlying stock at the exercise price.
• The sale price of $104.24 per share is significantly higher than the exercise prices of $19.19 and $12.17, demonstrating substantial personal profit from long-held options.

Negatives

• The CFO sold 24,765 shares, resulting in a net decrease of 24,765 shares from his direct beneficial ownership after accounting for the option exercises.
• Insider selling, even for personal financial planning, can sometimes be interpreted by the market as a lack of confidence or a signal that the stock may be nearing a peak.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future performance, as it is a report of an insider transaction.

Industry Context

StockSavvy.ai notes that insider transactions, such as those reported on Form 4, are closely watched by investors for signals regarding management's perception of the company's value. While option exercises and subsequent sales are common for executive compensation and personal financial planning, a net reduction in direct beneficial ownership can sometimes be viewed with caution, especially if it's a significant portion of an insider's holdings.

Comparison to Industry Standards

• StockSavvy.ai observes that it is standard practice for executives in publicly traded companies to exercise stock options as part of their compensation packages and subsequently sell shares for liquidity or diversification.
• The significant difference between the exercise prices ($19.19 and $12.17) and the sale price ($104.24) is typical for successful long-term equity incentive plans, reflecting substantial stock appreciation.
• This type of transaction is a routine part of executive compensation realization across various industries.

Stakeholder Impact

• Shareholders may interpret the insider sale as a signal, potentially influencing short-term trading sentiment. However, the transaction also demonstrates the profitability of the company's stock options for executives, which can be seen positively regarding long-term value creation.
• Employees: The exercise and sale of options by a senior executive highlight the value of equity compensation, which can be a motivator for other employees with similar incentives.

Next Steps

• The remaining three quarters of the stock option granted on April 18, 2022, will continue to vest in equal monthly installments through April 18, 2026, subject to the Reporting Person's continued service.
• The stock option granted on January 16, 2023, will continue to vest in 48 equal monthly installments following the date of grant, subject to the Reporting Person's continued service.

Key Dates

Keywords

Protagonist Therapeutics, PTGX, Asif Ali, CFO, Insider Trading, Stock Options, Share Sale, SEC Form 4, Equity Compensation